A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension. - Schachar, Ronald A.; Raber, Susan; Courtney, Rachel; Zhang, Min (Current Eye Research, 2011)